Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 2,267,894 thousand, an increase of 0.9% compared to RMB 2,247,282 thousand for the same period in 2023[2] - Adjusted net loss for the period was RMB 89,801 thousand, a reduction of 23.5% from RMB 117,351 thousand in the prior year[2] - Adjusted net loss margin improved to (1.7%) from (2.0%), an improvement of 0.3 percentage points[2] - Gross profit for the six months ended June 30, 2024, was RMB 751,736 thousand, compared to RMB 682,913 thousand in 2023, reflecting a gross margin increase[2] - Basic and diluted loss per share for the period was RMB 0.06, compared to RMB 0.08 in the same period last year[4] - For the six months ended June 30, 2024, total customer contract revenue amounted to RMB 2,267,894 thousand, a slight increase from RMB 2,247,282 thousand for the same period in 2023, representing a growth of approximately 0.9%[12] - The net loss for the first half of 2024 narrowed by approximately 23.5%, resulting in a loss of RMB 89.8 million compared to a loss of RMB 117.6 million in the same period last year[27] - Revenue from the fast drug business reached RMB 2,210.1 million, reflecting a year-on-year growth of 1.2% from RMB 2,184.6 million[27] - Revenue from business distribution increased by 11.5% to RMB 274.3 million, up from RMB 246.0 million in the previous year[29] - Total revenue increased by 0.9% to RMB 2,267.9 million for the six months ended June 30, 2024, compared to RMB 2,247.3 million for the same period in 2023[38] - Revenue from pharmaceutical and healthcare businesses rose by 1.2% to RMB 2,210.1 million for the six months ended June 30, 2024, from RMB 2,184.6 million for the same period in 2023[38] Expenses and Costs - Total comprehensive expenses for the period amounted to RMB 128,546 thousand, down from RMB 136,810 thousand in the previous year[3] - The cost of goods sold for the six months ended June 30, 2024, was RMB 1,515,673 thousand, compared to RMB 1,550,168 thousand in 2023, indicating a decrease of about 2.2%[13] - Employee benefits expenses totaled RMB 258,927 thousand for the six months ended June 30, 2024, slightly down from RMB 261,723 thousand in 2023, reflecting a decrease of approximately 1.1%[13] - Fulfillment expenses increased by 5.1% to RMB 223.3 million for the six months ended June 30, 2024, from RMB 212.4 million for the same period in 2023[41] - Sales and marketing expenses increased by 4.4% from RMB 465.2 million for the six months ended June 30, 2023, to RMB 485.9 million for the six months ending June 30, 2024, representing 21.4% of revenue[42] - R&D expenses decreased by 20.5% from RMB 30.7 million for the six months ended June 30, 2023, to RMB 24.4 million for the six months ending June 30, 2024, accounting for 1.1% of revenue[43] - General and administrative expenses decreased by 1.3% from RMB 127.8 million for the six months ended June 30, 2023, to RMB 126.1 million for the six months ending June 30, 2024, representing 5.6% of revenue[44] - Other income decreased by 64.7% from RMB 19.0 million for the six months ended June 30, 2023, to RMB 6.7 million for the six months ending June 30, 2024[45] - Other income increased by 6.8% from RMB 23.7 million for the six months ended June 30, 2023, to RMB 25.3 million for the six months ending June 30, 2024[46] - Financial costs increased by 12.8% from RMB 3.9 million for the six months ended June 30, 2023, to RMB 4.4 million for the six months ending June 30, 2024[47] - Income tax expenses increased by 64.9% from RMB 3.7 million for the six months ended June 30, 2023, to RMB 6.1 million for the six months ending June 30, 2024[48] Assets and Liabilities - The company's total assets as of June 30, 2024, were RMB 2,990,393 thousand, a decrease from RMB 3,064,768 thousand as of December 31, 2023[6] - Cash and cash equivalents increased to RMB 1,233,580 thousand from RMB 1,185,898 thousand at the end of 2023[5] - Non-current assets totaled RMB 662,388 thousand, down from RMB 692,758 thousand at the end of 2023[5] - The company's equity attributable to owners decreased to RMB 1,945,241 thousand from RMB 2,037,422 thousand[6] - Trade receivables as of June 30, 2024, amounted to RMB 110,183,000, a slight decrease from RMB 113,382,000 as of December 31, 2023[21] - The company reported total trade and other payables of RMB 771,602,000 as of June 30, 2024, compared to RMB 774,084,000 at the end of 2023, indicating a marginal decrease[23] - The company recognized a deferred tax asset of RMB 2,163,000 for the current period, compared to a deferred tax asset of RMB 3,742,000 in the previous year, indicating a decrease of approximately 42.3%[16] - The company's expected credit loss provision for trade receivables was RMB 3,598,000 as of June 30, 2024, compared to RMB 1,056,000 at the end of 2023, indicating a significant increase in expected credit losses[22] Operational Highlights - The online direct sales channel generated revenue of RMB 1,612.7 million, showing a slight increase of 0.4% from RMB 1,606.0 million in the previous year[30] - The platform accumulated approximately 4.36 million registered users, with 3.5 million health consultations recorded during the reporting period[27] - The company has initiated online national medical insurance payment services in cities such as Beijing, Shanghai, Shenzhen, and Foshan, enhancing its market presence[26] - The company aims to strengthen its ecosystem by integrating medical, testing, pharmaceutical, and insurance services to meet residents' health needs[28] - The company has established partnerships with over 6,000 pharmaceutical and distribution companies to enhance product diversity and affordability[29] - The company provided over 3.5 million online consultations during the reporting period, supported by a medical team of over 800 doctors and 400 pharmacists[34] Shareholder Information - The company has not declared or recommended any dividends to ordinary shareholders for the first half of 2024, consistent with the previous year[25] - The company adopted a share incentive plan on May 1, 2020, involving a total of 87,993,330 shares, representing approximately 6.56% of the total issued share capital as of June 30, 2024[65] - The company also adopted a restricted share unit plan on June 27, 2023, involving up to 26,829,457 shares, representing approximately 2.0% of the total issued share capital as of June 30, 2024[65] - The company successfully raised a net amount of approximately HKD 341.6 million from the global offering, issuing a total of 33,537,000 shares at a price of HKD 12.00 per share[66] - 45% of the net proceeds, amounting to HKD 153.7 million, is allocated for business expansion, including the development of a smart pharmacy network[66] - 20% of the net proceeds, equivalent to HKD 68.3 million, is designated for potential investments, acquisitions, or strategic collaborations to expand the healthcare value chain[66] - As of June 30, 2024, HKD 60.9 million of the net proceeds has been utilized, leaving HKD 23.8 million unutilized[66] - The company does not recommend the distribution of an interim dividend for the six months ending June 30, 2024[71] Governance and Compliance - The audit committee, consisting of three independent non-executive directors, oversees the financial reporting process and internal controls[72] - The company has complied with the corporate governance code, although the roles of Chairman and CEO are held by the same individual[67] - No significant events occurred after June 30, 2024, that would impact the financial position of the company[71] - The company has not engaged in any purchase, sale, or redemption of its listed securities during the six months ending June 30, 2024[69] - The audit committee reviewed the unaudited condensed consolidated financial statements for the six months ending June 30, 2024[73] - The group’s interim financial report for the six months ended June 30, 2024, has been reviewed by Deloitte according to the International Accounting Standards Board's International Review Standard 2410[74] - The interim results announcement will be published on the Hong Kong Stock Exchange and the company's website[74] - The interim report for the six months ended June 30, 2024, will be sent to shareholders who have requested printed versions[74]
叮当健康(09886) - 2024 - 中期业绩